Diagnosis and Initial Treatment of CLL

Peter Hillmen, MD, PhD from the University of Leeds, Leeds, UK is joined by Richard Furman, MD, Weill Cornell Medical College, New York, NY and Stephen P. Mulligan, MBBS, MD, FRACP, FRCPA, University of Sydney, Sydney, Australia to review and discuss the thought-provoking session on ‘Diagnosis and Initial Treatment of CLL’ at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY. Together the experts cover the topics of the session, including the importance of mutational analysis and selecting the best treatment combinations for chronic lymphocytic leukemia (CLL) patients based on their mutational status. In addition, they discuss the value of minimal residual disease (MRD) as a prognostic marker and how guidelines will change in the coming years as more novel agents and treatment combinations are used in practice.

Share this video